BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10396301)

  • 1. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
    Ross JS; Fletcher JA
    Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS; Fletcher JA
    Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.
    Ross JS; Fletcher JA
    Oncologist; 1998; 3(4):237-252. PubMed ID: 10388110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
    Ross JS; Fletcher JA
    Semin Cancer Biol; 1999 Apr; 9(2):125-38. PubMed ID: 10202134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting.
    Hanna WM; Kahn HJ; Pienkowska M; Blondal J; Seth A; Marks A
    Mod Pathol; 2001 Jul; 14(7):677-85. PubMed ID: 11455000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer in the 21st century: neu opportunities and neu challenges.
    Schnitt SJ
    Mod Pathol; 2001 Mar; 14(3):213-8. PubMed ID: 11266529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer.
    Zadrozny M; Smolarz B; Romanowicz-Makowska H; Kozłowska E; Kulig A
    Pol J Pathol; 2002; 53(4):189-93. PubMed ID: 12597335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
    Benöhr P; Henkel V; Speer R; Vogel U; Sotlar K; Aydeniz B; Reiser A; Neubauer H; Tabiti K; Wallwiener D; Clare SE; Kurek R
    Anticancer Res; 2005; 25(3B):1895-900. PubMed ID: 16158923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.
    Ross JS; Fletcher JA; Linette GP; Stec J; Clark E; Ayers M; Symmans WF; Pusztai L; Bloom KJ
    Oncologist; 2003; 8(4):307-25. PubMed ID: 12897328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ; Hyjek E; Early E; Knowles DM
    Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of HER-2/neu in breast carcinoma].
    Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
    Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the HER-2/neu oncogene in gynecologic cancers.
    Cirisano FD; Karlan BY
    J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
    Arafah M
    Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.